Egypt ADPKD (Autosomal dominant polycystic kidney disease) Therapeutic Market Report 2022 to 2030

Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

$ 3999

The Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US$3 Mn in 2022, and is predicted to grow at a CAGR of 7.3% from 2023 to 2030, to US$5 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, healthcare infrastructure growth, and other factors. The industry is primarily dominated by players such as Otsuka Pharmaceuticals, AceLink, Palladio, Reata, Xortx, Regulus, Exelixis, Sanofi, and other players.

ID: IN10EGPH425 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Riddhi Solanki

Buy Now

Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at around US $3Mn in 2022 and is projected to reach US $5Mn in 2030, exhibiting a CAGR of 7.3% during the forecast period.

Autosomal dominant polycystic kidney disease (ADPKD), a genetic condition affecting numerous organs, is caused by mutations in the PKD1 and PKD2 genes. This genetic defect causes fluid-filled cysts to form within the kidneys, causing them to enlarge, a condition known as renomegaly. In most cases, ADPKD leads to renal failure (ESKD). Fatigue, pain, and recurring infections are common complaints. Though there is no apparent cure for this rare disorder, its symptoms can be managed and consequences avoided through effective therapy. Otsuka Pharmaceuticals' tolvaptan (Jinarc) is the only licensed medicine for ADPKD, demonstrating efficacy in certain patients by acting as a vasopressin blocker and lowering cyst formation. Pain management and lifestyle changes are further treatment approaches.

Egypt is a country situated in northeast Africa. The evidence suggests the overall prevalence of ADPKD is around 1/1,000 individuals in Egypt. The real estimates are thought to be higher due to underdiagnosis in a number of cases. The market is therefore driven by major factors like the rising prevalence of cases, the shifting healthcare landscape, improving access to treatments, and evolving treatment options in the industry. However, conditions such as high costs of treatment, a lack of specialist human resources, and others hinder the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in the prevalence of ADPKD: Epidemiological data estimates that the prevalence of ADPKD ranges from 1/1,000 individuals in Egypt. The actual estimates are believed to be higher due to underdiagnosis in several cases. These numbers are anticipated to result in patients requiring advanced treatments, resulting in the growth of the market.

Healthcare infrastructure growth: Egypt’s healthcare system is evolving, providing improved access to specialized care and diagnostic resources, potentially energizing the ADPKD therapeutics market. As the economy grows, healthcare spending in Egypt is expected to increase, enhancing the accessibility of ADPKD treatments and broadening their market presence.

Evolving treatment options: The development of novel therapies aimed at reducing ADPKD progression and combined treatments targeting different aspects of the condition could establish untapped market segments. Increased awareness among healthcare providers and patients regarding ADPKD and the available treatments drives market growth.

Increased awareness: Increasing public awareness and educational campaigns promote early diagnosis, enabling timely interventions and potentially widening the market for treatments focused on slowing the advancement of the disease. Groups such as the Egyptian Society of Nephrology and Transplantation (ESNT) work towards improving patient access and care, influencing evidence-based policy decisions by gathering data that propel the therapeutics market.

Market Restraints

High costs of treatment: Innovative treatments for ADPKD, notably gene therapy approaches, may incur significant costs. Despite universal health insurance coverage by the government, patients might encounter financial challenges. A considerable segment of Egypt's population resides below the poverty threshold, which further limits their ability to procure expensive ADPKD medications. This situation could restrict treatment access and hinder market advancement.

Lack of specialists: In underdeveloped areas of Egypt, patients with ADPKD face restricted access to specialized care and suitable treatment options due to the concentration of nephrologists and other experts in major cities. The disproportionate number of patients compared to available specialists can curtail consultation time and the quality of care provided to individuals with ADPKD.

Regulatory challenges: Understanding and manoeuvring through Egypt's pharmaceutical regulations can be complex and time-intensive, potentially slowing down the introduction of new ADPKD medications to the market. Moreover, the limited availability of comprehensive data on ADPKD prevalence and treatment outcomes in Egypt poses challenges for policymakers and healthcare providers in formulating effective strategies and resource allocation.

Healthcare Policies and Regulatory Landscape

Egypt's healthcare policy and regulatory structure are overseen by the Ministry of Health and Population (MoHP) and are primarily regulated through laws such as the Egyptian Medical Facilities Law, the Egyptian Drug Authority (EDA), and the Egyptian Diagnostics Clinical Laboratories Law. The healthcare system in Egypt has historically encompassed both the public and private sectors, with ongoing endeavours directed towards bolstering medical facilities, improving service delivery, and extending healthcare accessibility to underserved regions. The nation has implemented health policies and collaborated with the private sector to expand service offerings. The Egyptian Health System is currently undergoing significant transformations, prompting stakeholders to gain a deeper understanding of the existing framework and forthcoming developments. The recent endorsement of the Social Health Insurance Law aims to reduce out-of-pocket expenses and widen coverage. Although Egypt's healthcare market is primarily reliant on out-of-pocket payments, a shift towards increased public expenditure is anticipated.

Egypt's healthcare system faces several challenges in improving and safeguarding the health and well-being of its population. The government has placed emphasis on broadening social health insurance coverage and delivering cost-effective and efficient fundamental health services aligned with the critical health needs of the population.

Competitive Landscape

Key Players

Otsuka Pharmaceutical Co., Ltd
Regulus Therapeutics
Palladio Biosciences
Reata Pharmaceuticals
Galapagos NV
Exelixis Inc
AceLink Therapeutics, Inc
Sanofi
Xortx Therapeutics
Pano Therapeutics

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Segmentation

By Treatment

Pain & Inflammation Treatment
Kidney Stone Treatment
Urinary Tract Infection Treatment
Kidney Failure Treatment

By Route of Administration

Oral
Parenteral
Others

By End User

Hospitals
Speciality Clinics
Surgical Centres
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.